GlassScriptPhysician profile
Lauren E Martin
NPI 1851546469
$7,776.84
in general payments reported to CMS, 2019-2025
48 companies · $1,415 in 2025
The $1,415 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,544 · 2022: $1,705 · 2023: $1,527 · 2024: $1,586 · 2025: $1,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,515 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,514.62 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,207.53 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $914.45 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $795.88 | 2021-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $452.34 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $417.19 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $385.89 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $310.25 | 2021-2024 | |
| Esperion Therapeutics, INC. | $289.81 | 2021-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.49 | 2021-2025 | Jardiance, Jascayd |
| Glaxosmithkline, LLC. | $216.05 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Otsuka America Pharmaceutical, INC. | $195.32 | 2022-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.30 | 2021-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $177.14 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $156.63 | 2022-2025 | |
| Astellas Pharma US INC | $156.04 | 2021-2025 | Veozah, Myrbetriq |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $139.10 | 2021-2022 | |
| Vifor Pharma, INC. | $132.28 | 2021 | |
| Xeris Pharmaceuticals, INC. | $131.74 | 2021-2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $117.68 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Antares Pharma, INC. | $102.35 | 2021-2024 | Xyosted, Tlando, Nocdurna |
| Sumitomo Pharma America, INC. | $89.53 | 2023-2025 | Gemtesa |
| Daiichi Sankyo INC. | $83.91 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.62 | 2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $69.07 | 2021 | |
| Janssen Pharmaceuticals, INC | $63.04 | 2021-2024 | Xarelto |
| Exact Sciences Corporation | $46.32 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $45.99 | 2021-2022 | |
| Qorumpartners | $44.26 | 2022 | |
| Sanofi Pasteur INC. | $42.07 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $36.87 | 2025 | Voquezna |
| Genentech USA, INC. | $35.87 | 2021-2022 | |
| Fresenius USA Marketing, INC. | $35.81 | 2025 | Velphoro |
| Biohaven Pharmaceutical Holding Company LTD. | $34.85 | 2022 | |
| Medtronic, INC. | $34.45 | 2024-2025 | Minimed 780g |
| Shield Therapeutics INC | $33.43 | 2024-2025 | |
| Insulet Corporation | $32.39 | 2023 | Omnipod |
| Amarin Pharma, INC. | $29.61 | 2021 | |
| Axsome Therapeutics, INC. | $28.97 | 2025 | Auvelity |
| Abbott Laboratories | $28.72 | 2025 | Tacticath Ablation Catheter, Sensor Enabled |
| Clarus Therapeutics INC. | $28.57 | 2021 | |
| Paratek Pharmaceuticals, INC. | $24.25 | 2022 | |
| Seqirus USA INC | $22.39 | 2023 | Flucelvax Quadrivalent |
| Verity Pharmaceuticals INC. | $18.95 | 2025 | Tlando |
| Tolmar, INC. | $15.76 | 2025 | Jatenzo |
| Idorsia Pharmaceuticals US INC | $13.64 | 2023 | Quviviq |
| Corcept Therapeutics | $13.26 | 2021 | |
| Eisai INC. | $12.48 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.